第三代抗癫痫新药吡仑帕奈在中国获批！

Paraampanel is a highly selective, non-competitive AMPA glutamate receptor antagonist developed by Japan's Eisai. It is mainly used to treat epilepsy and was first approved for marketing by the US FDA in 2015. Epilepsy is one of the three major diseases of the human central nervous system. It is the third generation drug for the treatment of epilepsy and has remarkable effects.

Parampanel applied for clinical trials in July 2015 and submitted its marketing application in October 2018. On December 1, 2019, parampanel was officially launched in China. China's epilepsy treatment field officially welcomed the first non-competitive AMPA receptor antagonist. This drug brought new treatment methods and methods. Paraampanel is indicated for the add-on treatment of patients with partial-onset epilepsy (with or without secondary generalized seizures) in adults and children 12 years of age and older.

Systematic review of the effectiveness and safety of parampanel in the treatment of refractory partial seizures in epilepsy, including 5 studies with a total of 1500 patients. Meta-analysis results showed that the perampanel group's complete seizure-free rate and the percentage of patients whose seizure frequency was reduced by ≥50% were higher than those in the placebo group, and the difference was statistically significant. The main adverse reactions of perampanel include dizziness, drowsiness, headache, ataxia, nasopharyngitis, etc. The incidence of total adverse reactions in the perampanel 8 mg and 12 mg groups was higher than that of the placebo group, and the difference was statistically significant (P<0.05). Conclusion Parampanel can effectively reduce the frequency of epileptic seizures in the treatment of refractory partial seizures of epilepsy, has mild adverse reactions, and is basically tolerated by patients.

Up to now, parampanel has been approved by 55 countries around the world, and more than 200,000 patients have been treated with the drug, which is taken orally once a day. Whether it is focal epileptic seizures, generalized epileptic seizures, or some special types of epilepsy syndromes, parampanel has shown good treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: